Form 10-K Beam Therapeutics Inc. For: Dec 31
Tweet
Share
E-mailhttp://archive.fast-edgar.com/20240227/AE22D222ZM22JT42222S2Z42HRQTTK22B262
Filed on: February 27, 2024
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- H.C. Wainwright Reiterates Buy Rating on Beam Therapeutics Inc (BEAM)
- Beam Therapeutics Inc (BEAM) PT Raised to $240 at JPMorgan
- Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
